In 5723 children aged 6–47 months, a cell culture-derived quadrivalent influenza vaccine vs a meningococcal C comparator vaccine reduced RT-PCR-confirmed influenza (3.6% vs 6.1%; vaccine efficacy 41.3%). No serious adverse events were deemed related to it.
RCTn = 5,723
Põder et al. Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial